About this project
This is a pilot study led by Dr. Madeleine Cunningham and Dr. Chandra Menendez at the University of Oklahoma, in collaboration with the Iatrogenic Neuroimmune Disease Association (INIDA), that will investigate potential autoimmune mechanisms in PSSD, focusing on GPCR autoantibodies using the Cunningham Panel (now known as the Autoimmune Brain Panel). By testing a cohort of patients under an IRB-approved protocol, the goal is to generate objective biological data to help guide future research, and potential diagnostics and treatment approaches.
What is PSSD?
Post-SSRI sexual dysfunction (PSSD) is a debilitating medical condition characterized by persistent sexual dysfunction, genital numbness, and often severe cognitive symptoms such as emotional blunting, anhedonia, and cognitive impairment following the use of antidepressant medication.
These symptoms can significantly impair daily functioning and quality of life. Despite this, the condition remains poorly understood and under-researched, highlighting a critical need for further scientific investigation and recognition.
By supporting this project, you are directly contributing to advancing research into this condition.
For more visit www.inida.info
Funding
We are currently raising funds for the final assays needed to complete testing. Each assay costs $995, and these remaining tests represent the last step toward reaching our target sample size.
The study has now been IRB approved, and we are finalizing logistics as we move into the testing phase.
Due to updated logistical and operational costs, the total study budget has unfortunately exceeded the initial estimate, and additional funding is now required.
Where We Are Now
A very generous donor recently contributed $10,000 to the study, which covers the cost of 10 participants.
- 7 participants have already been tested
- 2 participants is in the process of being tested (self-funded)
This brings us to cost covered for 19 participants total at this stage.
Funding Goals
- ~$1,000 → reach 20 participants (minimum target)
- ~$6,000 → reach 25 participants (current primary goal)
- ~$11,000 → reach 30 participants (full target)
While our ultimate goal is 30 participants, our immediate focus is 25, which represents a meaningful and achievable milestone within the current timeframe. If reached efficiently, we may increase the goal from $6300 to $11300 (~$5,000 increase) to complete the cohort of 30 patients.
Any support helps us cover the remaining assay costs and ensures that as many participants as possible can be included.
For every $995 raised, it funds testing for one participant
$995 = 1 participant
Note: The total fundraising goal includes platform and payment processing fees to ensure full coverage of testing costs.
Optional: Self-Funding a Test
If you are able to contribute at or above the cost of a full panel, there is also an option (primarily for patients) to self-fund a test directly through Moleculera Labs ($995).
This helps avoid small losses from platform and processing fees and ensures the full amount goes toward testing. This option is entirely voluntary.
About INIDA
INIDA (Neuroimmune Disease Association) is an international, patient-led nonprofit (based in Finland) dedicated to advancing research into novel neuroimmune disorders such as PSSD. We coordinate and fund scientific research through community-driven crowdfunding.
Note: INIDA Research Fund (Norway) handles fundraising and transactions due to regulatory requirements.